#Netherlands #Amsterdam #CGM #SIBIONICS #GS3

SIBIONICS GS3: Redefining Glucose Monitoring

The recent ATTD 2025 conference in Amsterdam brought together innovative minds and the latest advancements in diabetes care. Among the most talked-about products was the SIBIONICS GS3, touted as the world's thinnest Continuous Glucose Monitor (CGM). With a depth of only 2.9 mm, comparable to a small coin, the GS3 stands out not just for its size but for the revolutionary technology it harnesses to aid diabetes management.

Key Features of SIBIONICS GS3

Ultra-Compact Design

With an ultra-lightweight build of merely 1.5 grams, the GS3 promises near-invisibility when worn. This makes it not only convenient but also a comfortable choice for those who need to monitor their glucose levels continuously.

Lightning-Fast Activation

The GS3 is designed for immediate usability. Its 3-second NFC connection allows users to pair it effortlessly with a variety of smartphones, ensuring accessibility for all.

Intelligent Insights

Empowered by advanced AI algorithms, the GS3 provides users with in-depth interpretations of their glucose data. This feature enhances effective self-management of glucose levels, marking a significant leap in diabetes care. Additionally, the device connects seamlessly with smartwatches and receivers, catering to a wide range of users, including children and the elderly.

Enhanced Reliability

Ongoing improvements in its algorithm increase the stability and accuracy of glucose monitoring, positioning the GS3 as a dependable solution for users striving to control their glucose levels consistently.

Clinical Insights Shared at ATTD 2025

At the conference, SIBIONICS organized a symposium where clinical experts discussed the implications of Continuous Glucose Monitoring technology in clinical settings. They shared significant research findings on CGM applications and the differentiation in glucose patterns among various patient groups. These insights pave the way for more personalized diabetes treatments, emphasizing the importance of Precision Medicine in diabetes care.

The symposium also unveiled preliminary findings on CKM, showcasing its potential in managing Type 1 diabetes for the first time during the conference. This indicates SIBIONICS's commitment to not just innovation but to evidence-based advancements in diabetes treatment.

A Vision for the Future

Since its inception in 2015, SIBIONICS has emerged as a leader in the medical device sector, driven by a mission to transform patient lives through innovative health technology. With offices in Shenzhen, China, and Irvine, California, a dedicated team of over 500 professionals, including more than 25% R&D scientists from top universities, continues to push the boundaries of health technology.

Dedicated to improving patient understanding of their health through continuous biosensors, intelligent algorithms, and intuitive software solutions, SIBIONICS exemplifies the future of diabetes management. The GS3 is a testament to their vision, promising a smarter, lighter, and more accurate glucose monitoring experience for diabetes patients worldwide.

For more on SIBIONICS and the groundbreaking GS3, visit SIBIONICS.